Clinical trials: Inflammation, Brain
Stroke, Fatigue
Post-stroke Fatigue, Inflammation, tDCS
Fatigue is a common condition after an individual has a stroke. While the negative impacts of post-stroke fatigue are well known, the knowledge of the causes of post-stroke fatigue and effective treatments for post-stroke fatigue…
- Conditions
- Stroke, Fatigue, Chronic Stroke, Stroke Sequelae
- Trial name
- NCT05330988
- Testing
- anodal transcranial direct current stimulation (a-tDCS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Giant Cell Arteritis
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
This study was designed to evaluate the efficacy and safety of secukinumab compared to placebo to maintain disease remission up to 28 weeks including corticosteroid tapering, as well as up to 1 year (52 weeks) in patients with…
- Trial name
- TitAIN (NCT03765788)
- Testing
- Secukinumab 300 mg, s.c., Prednisolone
- Where
- 11 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease, Oxidative Stress
Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease
The purpose of this study is to determine the effect of fish oil and the antioxidant alpha lipoic acid on factors in the blood that are associated with the progression of Alzheimer's Disease (AD).
- Conditions
- Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia
- Trial name
- NCT00090402
- Testing
- Fish Oil, Lipoic Acid
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Oregon Health and Science University
Obesity
Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity
The rate of obesity in the United States is high and is a risk factor for concurrent cognitive impairment and, in late life, dementias such as Alzheimer's disease.
- Trial name
- NIFOB (NCT04116229)
- Testing
- Oral glucose tolerance test, Cognitive testing, Magnetic resonance imaging
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Japanese Encephalitis
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains…
- Trial name
- NCT00319592
- Testing
- ChimeriVax™-JE vaccine, JE-VAX® vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi
Cardiovascular Disease
Cardiovascular Inflammation Reduction Trial
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic…
- Trial name
- CIRT (NCT01594333)
- Testing
- Methotrexate
- Where
- 470 sites in United States, Canada and 1 more
- Volunteers
- 4,786 people
- Sponsor
- Brigham and Women's Hospital
Japanese Encephalitis
Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age
This randomised, double-blind study is to be conducted on 96 subjects at multiple sites in India. Subjects will be enrolled by age group and randomised to either ChimeriVax™-JE (JE-CV) or JE Mouse Brain Derived Vaccine (JE-MBDV).
- Trial name
- NCT00441259
- Testing
- ChimeriVax™-JE, Japanese Encephalitis Inactivated Mouse Brain Vaccine
- Where
- 3 sites in India
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sanofi
Japanese Encephalitis, Japanese Encephalitis Virus Disease
Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers
The purpose of this study is to compare Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) with Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine [CD.JEVAX™]) after a single dose vaccination to…
- Trial name
- NCT01396512
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine, Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
- Where
- 6 sites in South Korea
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Japanese Encephalitis
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults.
- Trial name
- NCT00981175
- Testing
- Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diffuse Lewy Body Disease, Dementia With Lewy Bodies
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body.
- Conditions
- Diffuse Lewy Body Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
- Trial name
- NCT02702102
- Testing
- 11C-PBR28
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Columbia University
Japanese Encephalitis
Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.
- Trial name
- NCT00596102
- Testing
- Japanese Encephalitis purified inactivated vaccine
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Metabolism - Cerebral Energy
The Efficient Brain Study
Cerebral energy metabolism declines with advanced aging, and is implicated in age-related cognitive decline, Alzheimer's disease (AD), and other forms of neurodegenerative disease (Parkinson's disease).
- Trial name
- NCT02771366
- Testing
- Fermented Papaya Preparation, Granulated Sugar
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Florida
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the…
- Trial name
- NCT00776230
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Alzheimer's Disease
Imaging Tau in Alzheimer's Disease and Normal Aging
This study is being done to learn about tau tangles in Alzheimer's disease. A type of PET scan is used to measure the abnormal accumulation of protein called tau in the brain.
- Trial name
- NCT02884492
- Testing
- 18F-THK-5351, Lumbar Puncture (optional)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- William Charles Kreisl
Encephalitis
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
The primary objective is to assess the safety profile of IC51 in a pediatric population from regions where JEV is not endemic
- Trial name
- NCT01047839
- Testing
- IC51
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Depressive Symptoms, Inflammation
Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention
Cardiovascular disease and depression are some of the most costly illnesses to society, and caring for a loved-one with Alzheimer's disease has been associated with increased risk for both depression and cardiovascular disease.
- Trial name
- NCT01802554
- Testing
- Pleasant Events Program (PEP), Information Support (IS)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Japanese Encephalitis
Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine
The proposed study is a four-arm double-blind randomized controlled single center trial to evaluate, by examining post-vaccination seroprotection titers, the lot-to-lot consistency of three lots of Japanese Encephalitis live…
- Trial name
- NCT01567865
- Testing
- Vaccine produced in existing facility, Vaccine produced in new facility
- Where
- Bangladesh
- Volunteers
- 818 people, healthy volunteers welcome
- Sponsor
- PATH
Encephalitis
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
The primary objective is to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51 administered in two doses in a 28 days interval up to Month 7 after the first IC51…
- Trial name
- NCT01041573
- Testing
- IC51 Japanese Encephalitis, Havrix®720, Prevnar
- Where
- 2 sites in Philippines
- Volunteers
- 1,869 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Vaccine Responsiveness in Allergy, Vaccine Responsiveness During Allergy De-sensitization Treatment
TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Allergic patients especially those undergoing de-sensitization treatment have an altered immune responsiveness. The investigators aim to find out whether this influences immune responses to primary and booster vaccinations.
- Trial name
- NCT02511535
- Testing
- TBE booster vaccination
- Where
- Austria
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna